221 related articles for article (PubMed ID: 31009664)
1. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
McKesey J; Pandya AG
J Am Acad Dermatol; 2019 Aug; 81(2):646-648. PubMed ID: 31009664
[No Abstract] [Full Text] [Related]
2. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
Kim SR; Heaton H; Liu LY; King BA
JAMA Dermatol; 2018 Mar; 154(3):370-371. PubMed ID: 29387870
[No Abstract] [Full Text] [Related]
3. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Liu LY; Strassner JP; Refat MA; Harris JE; King BA
J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
[TBL] [Abstract][Full Text] [Related]
4. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
[No Abstract] [Full Text] [Related]
5. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Craiglow BG; King BA
JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib therapy for children with severe alopecia areata.
Dai YX; Chen CC
J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
[No Abstract] [Full Text] [Related]
7. [Pharmacology profile and clinical findings of tofacitinib citrate (Xeljanz® tablet 5 mg)].
Harada T; Nakamura H
Nihon Yakurigaku Zasshi; 2014 Sep; 144(3):133-41. PubMed ID: 25213614
[No Abstract] [Full Text] [Related]
8. Tofacitinib Treatment for Pretibial Myxedema.
Wang S; Chen X; Bai J; Sun Q; Fang H; Qiao J
JAMA Dermatol; 2024 May; 160(5):578-580. PubMed ID: 38568614
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
Olamiju B; Craiglow BG
Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
[TBL] [Abstract][Full Text] [Related]
10. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
[No Abstract] [Full Text] [Related]
11. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of tofacitinib for refractory Behçet's syndrome.
Liu J; Hou Y; Sun L; Li C; Li L; Zhao Y; Zeng X; Zhang F; Zheng W
Ann Rheum Dis; 2020 Nov; 79(11):1517-1520. PubMed ID: 32461206
[No Abstract] [Full Text] [Related]
14. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia.
Chen LC; Ogbutor C; Kelley KJ; Senna MM
J Am Acad Dermatol; 2024 Jun; 90(6):1260-1262. PubMed ID: 38311243
[No Abstract] [Full Text] [Related]
15. Medical and Maintenance Treatments for Vitiligo.
Passeron T
Dermatol Clin; 2017 Apr; 35(2):163-170. PubMed ID: 28317526
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Liu LY; Craiglow BG; King BA
J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
[No Abstract] [Full Text] [Related]
18. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
[TBL] [Abstract][Full Text] [Related]
20. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]